STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Item 7.01 Regulation FD Disclosure.

On January17, 2018, Strongbridge Biopharma plc (the “Company”) held a conference call with investors (the “Investor Call”) to discuss its recent acquisition of the U.S. and Canadian rights to MACRILEN™ (macimorelin) from Aeterna Zentaris Inc. (the “Macrilen Acquisition”) and the amendment of its existing senior credit facility with CRG LP (the “Term Loan Amendment”) in connection therewith. The Macrilen Acquisition and Term Loan Amendment and call-in details for the Investor Call were announced in a press release earlier that day, which was filed as an exhibit to a Current Report on Form8-K..

The Company is furnishing an investor presentation that includes a description of MACRILEN™. The presentation also includes an estimate of the Company’s pro forma cash position as of December31, 2017 of $77 million, after taking into account anticipated net incremental proceeds from the Term Loan Amendment and expenses related to the Macrilen Acquisition. This information was also disclosed on the Investor Call. A copy of the investor presentation is attached as Exhibit99.1 to this Current Report on Form8-K and will also be made available on the Company’s website.

The information in this Current Report on Form8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, as amended, except as expressly set forth by specific reference in such filing. The information set forth herein will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

ExhibitNo.

Description

99.1

Investor Presentation dated January17, 2018


Strongbridge Biopharma plc Exhibit
EX-99.1 2 a18-3399_1ex99d1.htm EX-99.1 Exhibit 99.1  Strongbridge Biopharma plc January 2018   Forward-looking statements This document contains forward-looking statements relating to the Company’s strategy,…
To view the full exhibit click here

About STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP)

Strongbridge Biopharma plc, formerly Cortendo plc, is a development-stage biopharmaceutical company. The Company is engaged in advancing its product candidates through clinical development. The Company is focused on the development, in-licensing, acquisition and eventual commercialization of several complementary products and product candidates within franchises that target rare diseases. Its principal focus is to build its rare endocrine franchise, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly. Its product candidate, COR-003 (levoketoconazole), is a cortisol synthesis inhibitor, indicated for the treatment of endogenous Cushing’s syndrome. It is conducting SONICS, a pivotal Phase III clinical trial for COR-003. Its product candidate, COR-005 (veldotide), is a multi-receptor targeted somatostatin analog (SSA) in Phase II clinical development for the treatment of acromegaly patients. Its product candidate also includes BP-2002.